Any current/future new fundraising through debt or equity?

The company has not explicitly announced any new fundraising through debt or equity in the provided transcript. Current financial position shows improving leverage: - Net debt-to-EBITDA ratio improved from 3.55x (March 2024) to 2.30x (September 2024). - On a combined basis (SeQuent and Viyash), debt-to-EBITDA is below 1.50x. Overall debt level expected to remain stable for a few quarters due to working capital investments supporting business expansion. Post-merger, the combined entity is expected to be financially strong, potentially debt-free in 1-2 years, though the company does not i

Any current/future capex/capital investment/strategic investment?

SeQuent and Viyash are focusing on expanding capacities, especially manufacturing intermediates and final stage APIs, with transfers to Viyash sites underway for quick scalability. Investments in R&D and operations over the last couple of years have resulted in new product filings and launches, indicating ongoing strategic product development. Capex has been low recently due to strong existing manufacturing infrastructure and free capacity, as highlighted by Viyash. Working capital investment is increasing modestly to support business growth, especially in Turkey and Spain markets. The merger

Future growth expectations in sales/revenue/volumes?

The company expects continued growth across most markets and businesses, with Q2 FY'25 revenues growing 6.6% YoY and H1 revenues up 11.7% YoY. Emerging markets show strong momentum, driven by selective price increases, targeted volume recovery (e.g., Turkey market), and expanded product portfolios. Indian formulation business posted a robust 25% YoY growth, with further impact from field force expansion expected towards Q4 FY'25. Post-merger with Viyash Lifesciences, the combined entity anticipates accelerated growth due to enhanced R&D capacity, manufacturing scale, and diversified product po

Future growth expectations in earnings/operating earnings/profits/EPS?

Q1 FY25 showed a significant turnaround with PAT turning positive, indicating strong momentum. FY26 is expected to witness notable growth at the PAT level, accelerated by the proposed merger with Viyash Lifesciences. EBITDA margins improved considerably in Q2 FY25, up 452 bps year-on-year, reflecting positive operating leverage. Combined entity post-merger will benefit from scale in R&D, manufacturing, and an expanded global footprint, supporting sustained earnings growth. Debt-to-EBITDA ratio is improving, providing financial flexibility for future growth investments without excessive

Viyash Scientific LtdQ2 FY25Pharmaceuticals & Biotechnology

Viyash Scientific Ltd Q2 FY25 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹224.55P/E: 44.8Market Cap: ₹9.9K CrSector: Pharmaceuticals & Biotechnology

Management growth scorecard

Revenue

Category 3

Margin

Category 1

Fundraise

N/A

Order

N/A

Capex

Yes

2 of 3 growth signals are positive.

Full analysis

Revenue guidance

Category 3

The company expects continued growth across most markets and businesses, with Q2 FY'25 revenues growing 6.6% YoY and H1 revenues up 11.7% YoY.
Emerging markets show strong momentum, driven by selective price increases, targeted volume recovery (e.g., Turkey market), and expanded product portfolios.
Indian formulation business posted a robust 25% YoY growth, with further impact from field force expansion expected towards Q4 FY'25.
Post-merger with Viyash Lifesciences, the combined entity anticipates accelerated growth due to enhanced R&D capacity, manufacturing scale, and diversified product portfolio.
Focus on moving from commodity intermediates to complex, regulatory-driven products to capture higher growth opportunities.
Oncology and complex new molecules expected to drive portfolio expansion over the next 1-2 years.
EBITDA and margins are improving, signaling quality growth likely to translate into improved profitability as volume growth picks up.

Margin guidance

Category 1

Q1 FY25 showed a significant turnaround with PAT turning positive, indicating strong momentum.
FY26 is expected to witness notable growth at the PAT level, accelerated by the proposed merger with Viyash Lifesciences.
EBITDA margins improved considerably in Q2 FY25, up 452 bps year-on-year, reflecting positive operating leverage.
Combined entity post-merger will benefit from scale in R&D, manufacturing, and an expanded global footprint, supporting sustained earnings growth.
Debt-to-EBITDA ratio is improving, providing financial flexibility for future growth investments without excessive leverage.
ESOP costs are expected to decline over the next 2-3 quarters, reducing dampening on profits.
Management is confident in achieving double-digit growth in formulations and steady state run rate in APIs, with overall revenue growing at 6.6% in Q2 and 11.7% in H1 FY25.
Operational efficiencies, strategic initiatives, and merger synergies position the company for sustained EPS growth in the near to medium term.

See what Viyash Scientific Ltd management said on margin guidance — free account, 30 seconds.

Fundraise plans

The company has not explicitly announced any new fundraising through debt or equity in the provided transcript.
Current financial position shows improving leverage:
- Net debt-to-EBITDA ratio improved from 3.55x (March 2024) to 2.30x (September 2024).
- On a combined basis (SeQuent and Viyash), debt-to-EBITDA is below 1.50x.
Overall debt level expected to remain stable for a few quarters due to working capital investments supporting business expansion.
Post-merger, the combined entity is expected to be financially strong, potentially debt-free in 1-2 years, though the company does not intend to remain debt-free permanently to support further growth investments.
Management is focused on reducing debt and financing future growth organically rather than immediate new fundraising.
No forward guidance on specific fundraising plans noted during the call.

Order book

The transcript does not provide explicit details on SeQuent Scientific Limited's current or expected order book or pending orders. However, some relevant insights include: - Ongoing demand growth, especially in regulated markets like the U.S., Europe, LATAM, China, and emerging markets. - Growth driven by new product launches, complex products, and oncology portfolio expansion over the next 1-2 years. - Positive trends in the CDMO (Contract Development and Manufacturing Organization) business, including animal healthcare opportunities. - The merger with Viyash Lifesciences is expected to create synergies, expand capacity (10+ U.S. FDA-approved sites), and accelerate growth. - Supply chain and market expansion initiatives underway, including geographical expansion such as in Japan. - The company is experiencing volume growth, price increases, and sales mix optimization. No specific numbers or timeline for order book or pending orders are disclosed in the call.

See what Viyash Scientific Ltd management said on order book — free account, 30 seconds.

Capex plans

Yes

SeQuent and Viyash are focusing on expanding capacities, especially manufacturing intermediates and final stage APIs, with transfers to Viyash sites underway for quick scalability.
Investments in R&D and operations over the last couple of years have resulted in new product filings and launches, indicating ongoing strategic product development.
Capex has been low recently due to strong existing manufacturing infrastructure and free capacity, as highlighted by Viyash.
Working capital investment is increasing modestly to support business growth, especially in Turkey and Spain markets.
The merger aims to create synergies that will increase capacity and operational efficiency over the next 12-15 months.
No explicit large capital expenditure plans disclosed, but continuous capability building and product acquisitions remain a strategic priority.
Clarifications on ESOP and merger-related costs suggest investment in talent and integration.
The company is open to acquisitions for growth but expects them to be disciplined and targeted.

Track Viyash Scientific Ltd — get its next earnings analysis in your feed

How does Viyash Scientific Ltd rank vs peers in Pharmaceuticals & Biotechnology?

Pro feature

ThisViyash Scientific Ltd

Rev 3Mar 1

See where Viyash Scientific Ltd sits in Pharmaceuticals & BiotechnologySee which companies these are, and every other name in the sector.Open rankings

How does Viyash Scientific Ltd rank in Pharmaceuticals & Biotechnology?

Compare Viyash Scientific Ltd against every Pharmaceuticals & Biotechnology company (Q2 FY25) on revenue, margins and earnings-call signals.

View Pharmaceuticals & Biotechnology leaderboard →

What Viyash Scientific Ltd's management said in earlier quarters

Others in Pharmaceuticals & Biotechnology this season

Lincoln Pharmaceuticals Ltd (Q2 FY27)
2,798.12 Lakhs increase (approximately 17.1% growth) . Key results statement takeaways from Lincoln Pharmaceuticals Ltd's Q2 FY27 results statement — and how it
Alivus Life Sciences Ltd (Q2 FY27)
Q2 FY27 Revenue from Operations: ₹6,820 million, up 16.0% year-on-year (YoY). Key investor presentation takeaways from Alivus Life Sciences Ltd's Q2 FY27 invest
Strides Pharma Science Ltd (Q2 FY27)
Q2FY27 Revenue: ₹14,297 million, up 17.1% YoY (Page 4, 15) . Key investor presentation takeaways from Strides Pharma Science Ltd's Q2 FY27 investor presentation
Laurus Labs Ltd (Q2 FY27)
2Q FY27 Revenue:** ₹2,206 crore, up 33% year-on-year (Y-o-Y) and 9% quarter-on-quarter (Q-o-Q). Key investor presentation takeaways from Laurus Labs Ltd's Q2 FY

Compare:vs Sun Pharma.Inds.vs Divi's Lab.vs Torrent Pharmaceuticals Ltd

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →